Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 460 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IV Ovarian Cancer Clear all
Not listed No phase listed Observational
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Circulating tumour DNA testing
Diagnostic Test
Lead sponsor
Walter and Eliza Hall Institute of Medical Research
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Interventions
Cisplatin, No treatment
Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
59
States / cities
Duarte, California • La Jolla, California • Newport Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced May 21, 2026, 5:33 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Testicular Germ Cell Tumor
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
EF5
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
aldesleukin, p53 peptide vaccine, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Paclitaxel(intravenous) + Carboplatin(intravenous), Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Drug
Lead sponsor
Gynecologic Oncology Trial & Investigation Consortium
Network
Eligibility
20 Years and older · Female only
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
9-aminocamptothecin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
Interventions
Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
Interventions
ziv-aflibercept
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma
Interventions
Avastin, Paclitaxel, Cisplatin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 5:33 PM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
14 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced May 21, 2026, 5:33 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Interventions
AVOVA-1, MC
Biological
Lead sponsor
Aivita Biomedical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Burbank, California • La Jolla, California • Newport Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ISIS 5132
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
2
States / cities
Duluth, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced May 21, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride, Hydroxychloroquine, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Vaginal Cancer, Vulvar Cancer
Interventions
topotecan hydrochloride, pharmacological study
Drug · Other
Lead sponsor
Steven Waggoner, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced May 21, 2026, 5:33 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
Interventions
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis, sargramostim
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced May 21, 2026, 5:33 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Anxiety Disorder, Worry, Uncertainty, Sleep Disorders, Insomnia, Fatigue, Pain, Depression, Cognitive-behavioral Therapy, Psychological Intervention, Esophageal Cancer, Pancreatic Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Ovarian Neoplasm, Stage III or IV Cervical or Uterine Cancer, Stage IIIB, IIIC, or IV Breast Cancer, Glioblastoma Multiforme, Relapsed Lymphoma, Stage III or IV Colorectal Cancer, Stage IIIC or IV Melanoma
Interventions
Cognitive-behavioral therapy for worry, uncertainty & insomnia
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced May 21, 2026, 5:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Vorinostat
Drug
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced May 21, 2026, 5:33 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
Interventions
Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
64
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced May 21, 2026, 5:33 PM EDT